Pfizer has confirmed that its manufacturing facility in Ringaskiddy in Cork will produce the new antiviral Covid-19 drug, if approved.
The update comes as the pharma giant said on Friday that its investigational antiviral drug was shown to reduce hospitalisation or death in non-hospitalised adults at risk of developing severe disease by 89%.
The new antiviral pill is named Paxlovid.
Pfizer has ceased further enrolment in the study due to the overwhelming efficacy shown in results and on advice from medical experts.
“We are pleased to confirm that Pfizer’s manufacturing facility in Ringaskiddy will support the global manufacturing and supply of our investigational Covid-19 oral antiviral candidate, should it be approved,” Pfizer said in a statement.
“Pfizer has begun investing – prior to regulatory authorisation and solely at our own risk and expense – in the manufacture of our potential Covid-19 oral antiviral candidate to help bring this potential treatment to patients as soon as possible.”
“Tackling the Covid-19 pandemic will likely require both vaccination and targeted treatments for those who contract the virus. Pfizer continues to dedicate its best-in-class global resources at all levels to work towards the development of responses to the Covid-19 pandemic, including the development of potential antiviral treatments.”